Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010092 | 0.92 | IDO1 (0.49) | FFAR4IDO1HDAC3HDAC1HDAC2 | |
| SCHEMBL30426988 | 0.89 | F13A1 (0.47) | FFAR4IDO1HDAC3HDAC1HDAC2 | |
| SCHEMBL5723611 | 0.85 | IDO1 (0.53) | FFAR4IDO1HDAC3HDAC1HDAC2 | |
| SCHEMBL17065498 | 0.83 | FFAR4 (0.51) | FFAR4FFAR1POLBNPSR1 | |
| SCHEMBL15094094 | 0.83 | POLQ (0.51) | FFAR4FFAR1 | |
| SCHEMBL892786 | 0.83 | IDO1 (0.53) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15532197 | 0.82 | FFAR4 (0.45) | FFAR4EPHX2PPARGFFAR1POLB | |
| SCHEMBL15532382 | 0.82 | POLQ (0.52) | FFAR4HDAC6PPARGFFAR1NPSR1 | |
| SCHEMBL9886215 | 0.81 | IDO1 (0.49) | FFAR4IDO1HDAC3HDAC1HDAC2 | |
| SCHEMBL29009985 | 0.81 | FFAR4 (0.41) | FFAR4IDO1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289868-B1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| CN-102076650-A | Carboxylic acid compound | DAIICHI SANKYO CO LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | FFAR4 733/4885IDO1 3790/4885HDAC3 150/4885 |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | FFAR4 26/4885IDO1 449/4885HDAC3 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.